Compounds > anaxirone
Page last updated: 2024-08-25

anaxirone and Neoplasms

anaxirone has been researched along with Neoplasms in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19905 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hilgard, P; Peukert, M; Pohl, J1
Fiebig, HH; Heim, ME; Peukert, M; Possinger, K; Queisser, W; Wander, HE1
Crespeigne, N; Decoster, G; Dodion, P; Gerard, B; Kenis, Y; Lambert, M; Nicaise, C; Rozencweig, M1
Cunningham, D; Forrest, GJ; Gilchrist, NL; Kaye, SB; Setanoians, A; Soukop, M; Stuart, JF1
Bach, F; Cavalli, F; Hansen, HH; Hansen, SW; Kaplan, S1

Other Studies

5 other study(ies) available for anaxirone and Neoplasms

ArticleYear
alpha-/beta-Triglycidyl-urazol (TGU, NSC 332488, I.N.N.: ANAXIRONE): a new chemotherapeutic agent.
    Cancer treatment reviews, 1984, Volume: 11, Issue:2

    Topics: Alkylating Agents; Animals; Antineoplastic Agents; Drug Evaluation; Drug Evaluation, Preclinical; Humans; Kinetics; Metabolic Clearance Rate; Mice; Neoplasms; Neoplasms, Experimental; Rats; Triazines; Triazoles

1984
Phase-II studies of 1,2,4-triglycidylurazol (TGU) in solid tumors. Phase-II Study Group of the Association of Medical Oncology of the German Cancer Society.
    Onkologie, 1986, Volume: 9, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasms; Prognosis; Triazoles

1986
Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
    Cancer treatment reports, 1986, Volume: 70, Issue:5

    Topics: Adult; Aged; Anemia; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Injections, Intravenous; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia; Triazoles

1986
A clinical and pharmacokinetic phase I study of 1,2,4-triglycidylurazol (TGU, NSC 332488).
    European journal of cancer & clinical oncology, 1986, Volume: 22, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Kinetics; Male; Middle Aged; Neoplasms; Triazoles

1986
Phase I trial of 1,2,4-triglycidylurazol (TGU, NSC 332488): a new triepoxide cytostatic agent.
    European journal of cancer & clinical oncology, 1985, Volume: 21, Issue:3

    Topics: Adult; Aged; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Phlebitis; Thrombocytopenia; Triazoles

1985